Cancer Therapeutics Market to Hit USD 620.32 Billion by 2035 as Precision Cancer Care Gains Momentum

Overview 

According to DataM Intelligence, the global cancer therapeutics market was valued at USD 189.34 billion in 2025 and is projected to reach USD 620.32 billion by 2035, expanding at a CAGR of 12.6% during 2026–2035. The cancer therapeutics market size reflects pharmaceutical and biological products used across solid tumors and hematologic malignancies, including chemotherapy, targeted therapies, monoclonal antibodies, immune-checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, cell therapies, hormonal therapies, radiopharmaceuticals and other advanced treatment modalities. 

The sector is increasingly shaped by biomarker-guided prescribing, expansion of advanced therapies into earlier treatment settings, longer treatment duration and the development of antibody-drug conjugates, cell therapies, bispecific antibodies and radiopharmaceuticals. Precision treatment strategies are also expanding the use of molecular and protein biomarkers to identify patients eligible for specific therapies, while treatment sequencing and product-line expansion are becoming increasingly important to commercial performance. 

Get More Insights from the Full Research Report: 

https://www.datamintelligence.com/research-report/cancer-therapeutics-market?indhu  

Recent Developments  

• August 2026, Pfizer, Eli Lilly, AstraZeneca, Roche and Johnson & Johnson announced major U.S. investment commitments covering manufacturing, research infrastructure and pharmaceutical production. Collectively, the companies pledged around US$500 billion, reinforcing domestic oncology manufacturing and R&D capacity amid growing demand for innovative cancer therapeutics. 

• August 2026, Merck & Co. reported continued strength in its oncology business, with Keytruda and Keytruda QLex generating approximately US$8.3 billion in second-quarter sales. The company is also preparing for clinical results from sac-TMT, a potential next-generation therapy intended to expand its oncology portfolio beyond Keytruda. 

• April 2026, Taiho Oncology, Taiho Pharmaceutical and Araris Biotech announced that the FDA had completed its IND review for ARC-02, an antibody-drug conjugate being developed for non-Hodgkin lymphoma. The clearance enabled the companies to initiate a Phase 1 dose-escalation study, highlighting continued development of targeted cancer therapeutics and ADC platforms. 

• April 2026, Taiho Pharmaceutical and Taiho Oncology advanced ARC-02 into Phase 1 development following FDA clearance of the investigational application. The program demonstrates Japan-linked pharmaceutical companies' increasing focus on antibody-drug conjugates and targeted oncology therapies for hematologic cancers. 

• 2026, Japanese pharmaceutical companies continued strengthening oncology R&D through targeted therapies, antibody-drug conjugates and next-generation treatment platforms. Industry programs are increasingly focused on precision medicine and therapies designed to address cancers with limited treatment options. 

Mergers & Acquisitions 

• GSK & Nuvalent – June 2026: GSK agreed to acquire Nuvalent, strengthening its oncology portfolio with targeted therapies for non-small-cell lung cancer and expanding its precision cancer-treatment capabilities.  

• GSK & RAPT Therapeutics – January 2026: GSK completed its acquisition of RAPT Therapeutics, adding small-molecule immunomodulators and strengthening its capabilities in cancer immunotherapy and immune-mediated disease treatments.  

• Eli Lilly & Curevo – May 2026: Eli Lilly agreed to acquire Curevo, adding its investigational vaccine technology to Lilly’s infectious-disease portfolio and broadening its capabilities in virus-related therapeutic development. 

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/cancer-therapeutics-market?indhu 

Segmentation 

By Therapy 

• Hormonal Therapy 

• Targeted Therapy 

• Chemotherapy 

• Radiotherapy 

• Immunotherapy 

• Others 

• Photodynamic Therapy 

• Other Therapies 

Cancer therapies encompass a range of treatment approaches designed to target, control, or eliminate cancer cells. Increasing use of targeted therapies, immunotherapy, hormonal therapy, chemotherapy, radiotherapy, and emerging treatment approaches is expanding options for patients across different cancer types. 

By Cancer Type 

• Breast Cancer 

• Lung Cancer 

• Prostate Cancer 

• Blood Cancer 

• Cervical Cancer 

• Malignant Meningioma 

• Head and Neck Cancer 

• Others 

Cancer therapeutics are developed and used across a broad range of malignancies with different biological characteristics and treatment requirements. Growing research and treatment development across breast, lung, prostate, blood, cervical, brain, and head and neck cancers are supporting demand for diverse therapeutic approaches. 

By Distribution Channel 

• Hospital Pharmacies 

• Retail Pharmacies 

• Online Pharmacies 

• Others 

Distribution channels facilitate the availability of cancer therapies to patients across healthcare settings. Hospital pharmacies remain important for specialized and administered treatments, while retail and online pharmacies support the distribution of eligible oral and supportive cancer medications. 

By End-User 

• Hospitals 

• Cancer Centers 

• Research Institutes 

Hospitals, cancer centers, and research institutes play important roles in cancer diagnosis, treatment, clinical research, and therapeutic development. Increasing specialization of oncology care and continued research into innovative cancer treatments are supporting demand across these end-user settings. 

By Region 

• North America 

• Europe 

• Asia-Pacific 

• South America 

• Middle East & Africa 

Regional cancer therapeutics demand is influenced by cancer prevalence, healthcare infrastructure, treatment accessibility, pharmaceutical research, and investment in oncology care. Expanding healthcare capabilities and the development of innovative treatment options are supporting market opportunities across major regions. 

Competitive Landscape 

Competition is shaped by the commercial strength of established oncology franchises, clinical-stage pipelines, biomarker coverage, treatment-line expansion, product differentiation and lifecycle-management strategies. Leading pharmaceutical companies are competing across immunotherapy, targeted medicines, antibody-drug conjugates, hormonal therapies, cell therapies and radiopharmaceuticals. The competitive environment is also being influenced by patent expiries, generic and biosimilar competition, new formulations and expansion of established therapies into earlier stages of disease. 

Top 5 Key Players 

• Merck & Co.  

• Bristol Myers Squibb  

• Roche  

• AstraZeneca  

• Johnson & Johnson 

Company Profiles 

• Merck & Co. – Merck is a major oncology player with Keytruda as one of its leading cancer-treatment franchises. The company continues to strengthen its oncology portfolio through expansion into earlier-stage and metastatic cancers, while the subcutaneous Keytruda Qlex formulation supports product lifecycle development and broader treatment convenience. 

• Bristol Myers Squibb – Bristol Myers Squibb has a broad oncology portfolio spanning immune-checkpoint inhibitors, targeted therapies and cellular treatments. Its presence in CAR-T therapy and hematologic malignancies strengthens its position across both established and advanced cancer-treatment modalities. 

• Roche – Roche maintains a strong position in oncology through targeted therapies, monoclonal antibodies, immunotherapies and antibody-drug conjugates. Its portfolio covers several major solid tumors and hematologic malignancies, supported by continued development of biomarker-driven treatment approaches. 

Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/cancer-therapeutics-market?indhu 

Regional Analysis: Europe 

Europe represents a major regional market but is neither the largest nor the fastest-growing region in the forecast period. The report identifies North America as the largest market and Asia-Pacific as the fastest-growing region. However, the supplied report content does not provide a specific percentage for Europe’s market share, so an unsupported percentage has not been added. 

European demand is supported by established healthcare systems, specialist oncology centers, access to innovative medicines and a broad presence of pharmaceutical companies. Major markets include Germany, France, Italy, Spain and the United Kingdom. At the same time, commercial uptake can differ between countries because regulatory approval does not automatically translate into reimbursement or unrestricted patient access. 

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-therapeutics-market?indhu 

Conclusion 

The global oncology sector is moving toward increasingly precise, biomarker-driven and treatment-specific approaches. Established chemotherapy continues to play an important role, particularly in combination regimens and settings without validated targeted options, while immunotherapies, targeted medicines, antibody-drug conjugates, bispecific antibodies, cell therapies and radiopharmaceuticals are expanding the range of available treatments. 

Commercial opportunities are increasingly linked to treatment-line expansion, product penetration, biomarker eligibility, treatment duration and lifecycle management. At the same time, patent expiries, biosimilar and generic competition are expected to redistribute revenue from mature products toward newer formulations, combinations and next-generation therapies. 

With North America maintaining the largest position and Asia-Pacific showing the fastest expansion, regional access, reimbursement, treatment infrastructure and adoption of advanced oncology products will remain important to the long-term cancer therapeutics market forecast. The combination of established franchises and rapidly developing treatment modalities is expected to keep the cancer therapeutics industry highly competitive through 2035.